Douglas Carl Fisher - 08 Oct 2021 Form 4 Insider Report for PHOENIX BIOTECH ACQUISITION CORP. (CERO)

Role
President
Signature
/s/ Chris Ehrlich, as attorney-in-fact
Issuer symbol
CERO
Transactions as of
08 Oct 2021
Net transactions value
$0
Form type
4
Filing time
12 Oct 2021, 19:31:51 UTC
Previous filing
05 Oct 2021
Next filing
31 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PBAX Class A common stock Other +10,000 10,000 08 Oct 2021 By Phoenix Biotech Sponsor, LLC F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PBAX Class B Common Stock Other +100,000 100,000 08 Oct 2021 Class A Common Stock 100,000 By Phoenix Biotech Sponsor, LLC F1, F3, F4
transaction PBAX Warrants Other +5,000 5,000 08 Oct 2021 Class A Common Stock 5,000 $11.50 By Phoenix Biotech Sponsor, LLC F1, F3, F5, F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Allocated to the reporting person as a member of Phoenix Biotech Sponsor, LLC.
F2 These shares underlie 10,000 units of the issuer purchased by the reporting person.
F3 Held directly by the issuer's sponsor, Phoenix Biotech Sponsor, LLC, of which the reporting person is a member. The reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for any other purpose.
F4 The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to certain adjustments described in the issuer's charter documents and have no expiration date.
F5 These warrants underlie 10,000 units of the issuer purchased by the reporting person.
F6 The warrants will become exercisable at the later of 30 days after the consummation of the issuer's initial business combination or 12 months from the completion of the issuer's initial public offering.
F7 The warrants will expire five years after the consummation of the issuer's initial business combination or earlier upon redemption of all of the issuer's outstanding Class A common shares or the issuer's liquidation.